Why the study?
Does continuous intravenous lidocaine stabilize AV conduction and prevent malignant arrhythmias in a newborn with congenital LQTS and 2:1 AV block?
Does continuous intravenous lidocaine stabilize AV conduction and prevent malignant arrhythmias in a newborn with congenital LQTS and 2:1 AV block?
Continuous intravenous lidocaine may serve as an effective adjunctive therapy for managing refractory arrhythmias in newborns with congenital LQTS and AV conduction abnormalities.
May offer alternative in beta-blocker-intolerant neonatal LQTS with AV block; hypothesis-generating and requires prospective validation.
Congenital long QT syndrome (LQTS) is a rare hereditary cardiac disorder characterized by prolongation of the QT interval on electrocardiogram (ECG), predisposing affected individuals to life-threatening arrhythmias. We present a case of a newborn with congenital LQTS and 2:1 atrioventricular (AV) block who presented with bradycardia and QT prolongation. Continuous intravenous lidocaine infusion was initiated, because of hypoglycemia with beta-blockers, resulting in stabilization of AV conduction and prevention of malignant arrhythmias. This case underscores the potential utility of lidocaine as an adjunctive therapy in managing refractory arrhythmias in newborns with congenital LQTS and AV conduction abnormalities.
No takes yet. Share an insight, caveat, or question.
Mohsin et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: